`
`___________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`___________________
`
`APOTEX, INC.
`Petitioner,
`v.
`
`UCB BIOPHARMA SPRL
`Patent Owner.
`U.S. Patent No. 8,633,194 to Fanara et al.
`Issue Date: January 21, 2014
`Title: Pharmaceutical composition of piperazine derivatives
`
`Inter Partes Review No.: IPR2019-00400
`
`PETITIONER’S NOTICE OF DEPOSITION OF
` DR. SARFARAZ NIAZI
`
`1
`
`
`
`Pursuant to 37 C.F.R. § 42.53, Petitioner Apotex Inc. (“Petitioner”) hereby
`
`provides notice that it will conduct cross-examination by deposition of Dr. Sarfaraz
`
`Niazi, a witness of Patent Owner UCB Biopharma Sprl (“Patent Owner”). The
`
`deposition will begin on December 6, 2019 at 9:00 a.m. (unless otherwise agreed) at
`
`the offices of Fenwick & West LLP located at 902 Broadway Suite 14, New York,
`
`NY 10010-6035, and will continue until completed. In accordance with 37 C.F.R. §
`
`42.53(d)(1), the parties have conferred and have agreed upon this date and location
`
`for the cross-examination of Dr. Niazi.
`
`The cross-examination will be taken before a Notary Public or other officer
`
`authorized by law to administer oaths. The cross-examination will be recorded by
`
`stenographic and/or audio means. It may also be transcribed by real-time reporting
`
`software and recorded by a videographer.
`
`Dated: November 18, 2019
`
`Respectfully submitted,
`
`Katten Muchin Rosenman LLP
`
`By: /Alissa M. Pacchioli/
` Alissa M. Pacchioli
`Reg. No. 74,252
`
`2
`
`
`
`CERTIFICATION OF SERVICE ON PATENT OWNER
`
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4), and 42.105, the undersigned
`
`certifies that on November 18, 2019, a complete copy of the foregoing Notice was
`
`served via email to Patent Owner’s counsel at:
`
`James Trainor: jtrainor@fenwick.com
`
`Robert Counihan: rcounihan@fenwick.com
`
`Erica Sutter: esutter@fenwick.com
`
`Respectfully submitted,
`
`Katten Muchin Rosenman LLP
`
`By: /Alissa M. Pacchioli/
`
`Alissa M. Pacchioli
`Reg. No. 74,252
`
`